On July 23, 2026 Thyora Therapeutics reported to have emerged from stealth as a biotechnology company leveraging next-generation covalent chemistry, with a mission to accelerate clinical translation and create therapies for high-unmet medical needs. Founded on breakthrough discoveries published today in Science by scientists at Moffitt Cancer Center, the company is advancing an integrated platform that combines novel covalent chemistry with AI-enabled chemoproteomics to unlock a new generation of precision therapeutics.Thyora was co-founded by Justin M. Lopchuk, Ph.D., Andrii Monastyrskyi, Ph.D., and Derek Duckett, Ph.D., inventors of the company’s foundational technologies, together with biotechnology executive T.J. Langer, who serves as Chief Executive Officer. Together, the founders established Thyora to translate pioneering science into transformative medicines by integrating world-class chemistry, pharmacology and drug discovery expertise.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"When I first saw the science, I believed it represented one of those rare opportunities to build a company around discoveries that could fundamentally change an entire field," said T.J. Langer, Chief Executive Officer of Thyora Therapeutics. "The team has developed technologies with the potential to reshape how covalent medicines are discovered and developed and to reach disease targets long considered undruggable. We founded Thyora to bring those discoveries out of the laboratory and build a company capable of translating extraordinary science into transformative medicines for patients."
Coinciding with the company’s launch, researchers at Moffitt today published landmark findings in Science describing a novel strain-release bicyclobutane (BCB) chemistry that demonstrated exceptional cysteine selectivity while maintaining potent target engagement and improved drug-like properties in preclinical studies. The work establishes a promising new approach for designing safer, more selective covalent medicines and represents an important advance in the rapidly evolving field of targeted drug discovery.
To translate these discoveries into medicines, Thyora has entered into an exclusive agreement with Moffitt, securing worldwide rights to the foundational technologies underlying its platform, including:
The proprietary bicyclobutane (BCB) covalent warhead technology for the development of next-generation covalent modulators.
The Covalogic AI-enabled chemoproteomics discovery platform.
Related intellectual property developed by Thyora co-founders
Together, these complementary technologies create an integrated discovery platform capable of identifying, designing and optimizing highly selective covalent medicines against challenging disease targets.
"From the beginning, our goal was to create technologies that could expand what is possible in covalent drug discovery," said Derek Duckett, Ph.D., co-founder of Thyora Therapeutics and chair of the Drug Discovery Department at Moffitt. "Launching Thyora gives us the opportunity to build an enduring platform that continually generates innovative medicines based on these scientific advances."
Initially focused on oncology, Thyora is building a pipeline of differentiated precision covalent therapeutics while expanding the potential applications of its platform across additional serious diseases. By integrating proprietary chemistry, AI-enabled chemoproteomics and functional genomics, the company aims to create medicines with greater precision, improved selectivity and the potential to address important unmet medical needs.
(Press release, Thyora Therapeutics, JUL 23, 2026, View Source [SID1234669404])